ATR05

Ro52

Recombinant - sf21 cells

Alternate Names:

TRIM21 | Ro52 antigen | SSA2 | RoRNP

Uniprot IDs:
mRNA RefSeq:
Protein RefSeq:

Want to see pricing and place an order?

Register and then log-in

Have an enquiry about this product?

Go here

Product Information

Autoantibodies to the Ro (SSA) antigen are one of the most frequent serological autoimmune markers in rheumatic diseases. Anti-Ro-positive sera may contain two different types of autoantibody; those directed to a 60 kDa and those directed to a 52 kDa polypeptide component (referred to as Ro60 and Ro52 respectively). While the vast majority of Ro(SSA) positive sera react with both of these components, anti-Ro60 antibody has been reported to occur without anti-Ro52 antibody only in SLE sera whereas anti-Ro52 antibody has been reported to occur in the absence of anti-Ro60 antibody in idiopathic inflammatory myopathy, dermatomyositis and scleroderma.

Antibodies to Ro52 have been observed to occur not only monospecifically or with Ro(SSA)/La(SSB), but also concurrently with antibodies to Jo-1 and to other aminoacyl transferases, with anti-SRP, anti-PMScl, anti-CENP-B, anti-RNP and antihistones. The differing serological and clinical associations of anti-Ro52 and anti-Ro60 suggest that anti-Ro52 should be considered as an additional connective tissue disease serum marker, independent of anti-Ro60(SSA).

Ro52 is a member of the tripartite motif (TRIM) family of proteins. The TRIM motif includes three zinc-binding domains, a RING finger, a B-box type 1 and a B-box type 2, and a centre coiled-coil region (leucine zipper). TRIM proteins are believed to identify specific cell compartments through a process of homo-multimerisation. Other functional studies have suggested a role for a putative leucine zipper domain of Ro52 in protein dimer formation and inhibition of transcription activity, and involvement of Ro52 in the ubiquitin pathway.

Although autoantibodies are known to bind to multiple epitopes on the Ro52 protein, the leucine zipper domain and an area on the N-terminal side of it have been shown to constitute a prominent linear epitope.

Clinical Indications

Sjögren’s syndrome
Systemic Lupus Erythematosus
Rheumatoid Arthritis
Neonatal Lupus Syndrome
Dermatomyositis
Scleroderma

Certificate of Analysis

Please log in to view certificates of analysis for this item

References

  1. Tan, E.M. (1989) Adv. Immunol. 44, 93
  2. McCauliffe, D.P. & Sontheimer, R.D. (1993) J. Invest. Dermatol. 100,73
  3. Chan, E.K.L. & Buyon, J.P. (1994) Man. Biol. Markers Dis. (Kluwer Acad. Publ.) B1/1-18
  4. Ben-Chetrit, E. et al. (1990) Arthritis Rheum. 33, 349
  5. Slobbe, R.L. et al. (1991) Clin. Exp. Immunol. 86, 99
  6. Rutjes, S.A. et al. (1997) Clin. Exp. Immunol. 109, 32
  7. Frank, M.B. et al. (1999) J. Autoimmun. 12, 137
  8. Peene, I. et al. (2002) Ann. Rheum. Dis. 61, 1090
  9. Peene, I. et al. (2002) Ann. Rheum. Dis. 61, 929
  10. Reymond, A. et al. (2001) EMBO J. 20, 2140
  11. Rhodes, D.A. et al. (2002) Immunol. 106, 246
  12. Wang, D. et al. (2001) Biochim. Biophys. Acta 1568, 155
  13. Di Donato, F. et al. (2001) Int. J. Biochem. Cell Biol. 33, 924
  14. Fukuda-Kamitani, T. & Kamitani, T. (2002) Biochem, Biophys. Res.Comm. 292, 774
  15. Bozic, B. et al. (1993) Clin. Exp. Immunol. 94, 227
  16. McCauliffe, D.P. et al. (1994) J. Rheumatol. 21, 1073
  17. Ricchiuti, V. Et al. (1994) Clin. Exp. Immunol. 95, 397
  18. Frank, M.B. et al. (1994) Clin. Exp. Immunol.95, 390
  19. St Clair, E.W. et al. (1994) Arthritis Rheum. 37, 1373
  20. Blange, I. et al. (1994) J. Autoimmunity 7, 263
  21. Peek, R. et al. (1994) J. Immunol. 153, 4321
  22. Itoh, Y. et al. (1992) Autoimmunity 14, 89
  23. Kurien, B.T. et al. (2001) Scan. J. Immunol. 53, 268
  24. Ben-Chetrit, E. et al. (1988) J. Exp. Med. 167, 1560
  25. McCauliffe, D.P. at al. (1997) J. Rheumatol. 24, 860
  26. Pourmand, N. et al. (2000) Scan. J. Rheumatol. 29, 116

After a custom reagent?

Need to discuss specific protein requirements. Our team can help create tailored solutions to meet your diagnostic needs.